title: Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome.
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Després
authors.forename: Isabelle
authors.initials: I
authors.lastname: Lemieux
authors.forename: Agnès
authors.initials: A
authors.lastname: Pascot
authors.forename: Natalie
authors.initials: N
authors.lastname: Alméras
authors.forename: Martine
authors.initials: M
authors.lastname: Dumont
authors.forename: André
authors.initials: A
authors.lastname: Nadeau
authors.forename: Jean
authors.initials: J
authors.lastname: Bergeron
authors.forename: Denis
authors.initials: D
authors.lastname: Prud'homme
mesh_terms: D000328:Adult; D001824:Body Constitution; D002097:C-Reactive Protein / Q000032:analysis*; D003324:Coronary Artery Disease / Q000517:prevention & control; D015248:Gemfibrozil / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood*; D008875:Middle Aged; D009765:Obesity / Q000097:blood*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
chemical_list: D000960:Hypolipidemic Agents; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D015248:Gemfibrozil